



**Prescription Drug Coverage Determination Form**  
PEGintron  
Peg-Intron® (peginterferon alpha-2b)

Please fax the completed form to Mercy Health Plans' Pharmacy Department  
at 314-214-8201 or 1-800-647-2240.

**Patient Information**

Patient Name: \_\_\_\_\_ Date of Birth: \_\_\_\_\_  
Subscriber ID#: \_\_\_\_\_  
Address \_\_\_\_\_ City \_\_\_\_\_ State \_\_\_\_ Zip Code \_\_\_\_\_

**Physician Information**

Name: \_\_\_\_\_ Specialty: \_\_\_\_\_ Tax ID#: \_\_\_\_\_  
Office Address \_\_\_\_\_ City \_\_\_\_\_ State \_\_\_\_ Zip Code \_\_\_\_\_  
Telephone: \_\_\_\_\_ Fax: \_\_\_\_\_ Contact Person \_\_\_\_\_

Physician Signature (REQUIRED): \_\_\_\_\_ Date \_\_\_\_\_

Medication Information (requests for non-formulary agents will be considered for members having a documented failure or contraindication to preferred agents.)

Medication name: \_\_\_\_\_ J-code: \_\_\_\_\_  
Dose: \_\_\_\_\_ Directions: \_\_\_\_\_  
Expected Duration of Therapy: \_\_\_\_\_

**Prior Authorization Criteria:**

- |  |                              |                             |
|--|------------------------------|-----------------------------|
| 1. Does the patient have the diagnosis of chronic hepatitis C virus infection?   | <input type="checkbox"/> Yes | <input type="checkbox"/> No |
| 2. Is the physician aware that labeling recommends that all patients be monitored for evidence of depression?                            | <input type="checkbox"/> Yes | <input type="checkbox"/> No |
| 3. Does the patient have compensated liver disease?  | <input type="checkbox"/> Yes | <input type="checkbox"/> No |
| 4. Does the patient have detectable levels of hepatitis C virus RNA in the serum?  | <input type="checkbox"/> Yes | <input type="checkbox"/> No |
| 5. Is the patient Genotype-1?  | <input type="checkbox"/> Yes | <input type="checkbox"/> No |
| 6. Has the patient received at least 6 months of interferon therapy  | <input type="checkbox"/> Yes | <input type="checkbox"/> No |
| If yes:  |                              |                             |
| ▪ Did the patient have detectable hepatitis C (HCV) RNA (a viral load) in the serum after or at the end of the initial treatment period? | <input type="checkbox"/> Yes | <input type="checkbox"/> No |
| ▪ Did the patient experience a 2-log decrease in viral load?   | <input type="checkbox"/> Yes | <input type="checkbox"/> No |
| ▪ Was the patient treated with interferon hepatitis C in the past and has now relapsed?  | <input type="checkbox"/> Yes | <input type="checkbox"/> No |
| ▪ Has the patient received 12 months total of pegylated interferon?  | <input type="checkbox"/> Yes | <input type="checkbox"/> No |

Please provide any additional history or medical information that may support coverage (attach office notes as necessary): \_\_\_\_\_

---

Note: If approved coverage will be as specified in above criteria or through the end of the year (December 31, 20xx). Some medications may be subject to quantity limitations or restricted to certain pharmacies.